Index

α1-antitrypsin, 19
α-methyldopa, impact on anaesthesia, 190
α-fetoprotein, 86
abruption, see placental abruption
access to antenatal care, 10
access to laboratory facilities, 47
accuracy of BPM devices, 5
ACE inhibitors, 143
acidosis, compensatory metabolic, 191
activated protein C, 143
active management, see interventionist care
acute renal failure, 68
ADAM-12 as part of multivariable analysis, 89, 90
adverse conditions of pre-eclampsia, 39
age,
   as a risk factor, 78
   maternal, pre-eclampsia risk, 39
   paternal, 81
   see also gestational age
aggressive management, see interventionist care
aggressiveness, 144
airway,
   difficult, 196
   examination at initial assessment, 187
albumin, 19
   pre-eclampsia risk, 39
albuminuria, 22
alcohol, 101, 123
alfentanil, 197
alkalosis, respiratory, 191
ALT,
   serum levels, 43
   timing of delivery, 171
ambulance services, 126
ambulatory blood pressure measurement, 6
   use in community, 3
   vs. HBPM, 7
anaesthesia, 185–207
   awareness during, 201
   blood pressure monitoring after, 190
   central venous catheters, 191
   delayed complications, 201
   difficult airway, 196
   dural puncture, 201
   early assessment, 185
   early complications, 201
   early warning systems, 190
   for Caesarean delivery, 196, 395–9
   general anaesthesia, 196
   GRADE evaluation of best practice points, 400
   haemodynamic management, 197
   hypertensive response to intubation, 196
   initial assessment, 186
   international guidelines on recommendations for,
      402–5
   intravenous bolus of crystalloid, 198
   local anaesthetic infiltration, 200
   minimally invasive cardiac output monitoring
      devices, 191
   monitoring for, 187
   non-depolarising muscle relaxants, 197
   pharmacological agents used in pre-eclampsia and,
      190
   post-traumatic stress disorder after, 201
   postoperative complications, 202
   postpartum issues, 201
   prevention of hypertensive response to intubation,
      393
   priorities for, 206
   prolonged neuromuscular block, 197
   resuscitation equipment, 185
   systemic effects of pre-eclampsia on, 188–9
   transthoracic echocardiography, 191
   use of vasopressors, 198
analgesia,
   fetal well-being and, 191
   in labour, 191
   inhalation, 192
   intravenous, 203
   methods for, 186
   neuraxial, 204
   oral, 203
   pain-induced sympathetic response and
      hypertension, 191
   parenteral, 192
   patient-controlled, 193
   rectal, 203
   WHO analgesic ladder, 203
   wound infiltration, 204
angiogenic factor imbalance, 36, 86, 44
   future research priorities, 52
   pre-eclampsia definition and, 37
angiogenic factor imbalance continued
with circulating proteins, 90
angiotensin receptor blockers, 143
antenatal care,
  access to, 10
  attendance at, 9
  development of surveillance, 76
  first trimester ultrasound, 168
  health care worker staffing levels for, 9
  late presentation for, 47
  number of visits, 8
  pre-eclampsia prevention and low rates of, 110
  recommended components of, 9
  Scottish paradigm, 33
  screening for proteinuria, 20
  timing of initiation, 9
antiangiogenic factors, 86
antihypertensives,
  choice of agent, 136, 141
  commonly used agents, 142
  for pre-eclampsia prevention, 105, 316
  GRADE evaluation of best practice points, 365–7
  in non-severe hypertension, 140–4
  in severe hypertension, 135–40
  international clinical guidelines, 155, 370–81
  maternal outcomes after use, 142
  maternal side-effects, 143
  policy briefs, 368
  treatment wall chart, 349
  use during breastfeeding, 140
antioxidants, 103
antiphospholipid syndrome, 79,
  antiphospholipid antibody syndrome, 43
antithrombin, 148, 150
antithrombin III deficiency, 79
anxiety, 82
aspirin, 292, 318–321
  impact on anaesthesia, 190
  low-dose,
    and hypertensive disorders in pregnancy, 102
    combined with calcium supplementation, 106
    for pre-eclampsia prevention, 102, 105
  use in under-resourced settings, 110
assisted reproductive treatment, as a risk factor, 81
AST, serum levels, 43
asthma, 136, 141
atenolol, 143
  paediatric neurodevelopment and, 143
  attendance at antenatal care, 9
audit of practice, 150
auscultatory methods of blood pressure measurement, 4
automated blood pressure measurement devices, 5
automated testing of urinary dipsticks, 22
awareness, during anaesthesia, 201
β-lipoprotein, 19
bariatric surgery for obesity, 224
bed rest, 109, 125
behaviour and paediatric neurodevelopment, 218
best practice points,
  antihypertensives
    in non-severe hypertension, 152
    in severe hypertension, 152
  blood pressure measurement, 11
  care beyond 6 weeks after birth, 225
  care in 6 weeks after birth, 224
  diagnosis of hypertension, 11
  fluids, 152
  for anaesthesia and analgesia, 205
  for classification of pre-eclampsia, 46
  for diet lifestyle and place of care, 128
  for fluids drugs and transfusions, 365–7
  for risk factors and predictors, 91
  GRADE evaluation
    for anaesthesia, 400
    for classification of hypertensive disorders of pregnancy, 255–6
    for diet, 345
    for hypertension, 236–7
    for lifestyle, 345
    for mode of delivery, 383
    for place of care, 345
    for postpartum care, 410
    for preventing pre-eclampsia, 340–3
    for proteinuria, 250
    for timing of delivery, 383
  in proteinuria, 27
  mode of delivery, 177
  place of delivery, 176
  prevention of pre-eclampsia in low-risk women, 112
  prevention of pre-eclampsia in women at increased risk, 113
  timing of delivery, 176, 177
beta blockers, 141
  use with methyldopa, 142
betamethasone, 176
biomarkers,
  for pre-eclampsia, 44
  future research priorities, 51
  in multivariable prediction analyses, 88
  in univariable prediction analyses, 86, 87
birth weight, maternal, 79
  see also large for gestational age, small for gestational age
blindness, 68
blood film, for pre-eclampsia, 42
blood pressure,
  access to monitoring facilities, 47
  as a predictor, 83
  changes with gestational age, 1, 2
Index

Changes with parity, 2
Chocolate and, 103
Circadian rhythm, 1
Importance of repeat measurement, 2
In offspring after pre-eclampsia, 218
Invasive monitoring, 198
Maintenance in anaesthesia, 197
Monitoring after anaesthesia, 190
Timing of delivery, 171
With uterine artery PI as predictor, 89

Blood pressure measurement,
ABPM, 6
Accuracy of devices, 5
Aneroid devices, 5
Auscultatory methods, 4
Automated devices, 4
Choice of device during pregnancy, 5
Choice of device for setting, 5, 6
Comparison of ABPM and HBPM, 7
Cuff size for, 3, 240
HBPM, 6
Importance of repeat, 2
In the community, 3
In under-resourced settings, 7–10
International guidelines, 240–6
Position for, 3
Recalibration of devices, 5
Sample policy brief, 238
Settings, health facility, 5
Smartphone and tablet technologies, 8
Solar-powered devices, 8
Techniques for, 3–7
Body mass index,
Pre-eclampsia risk, 40
Pre-pregnancy, 79
Bradycardia,
Fetal, 195
Neonatal, 136, 137
Brain natriuretic peptide, 52
Breastfeeding,
Antihypertensive use during, 140
Hypertension management and, 216
Bronchopulmonary dysplasia, 69
After vaginal cf Caesarean delivery, 175
Bupivacaine-soaked sponges, 204

C-reactive protein, 86
Caesarean section,
After MgSO₄ use, 145
Anaesthesia for, 196, 395–9
At 37–42⁺⁰ weeks
Bronchopulmonary dysplasia and, 175
Choice of anaesthesia for, 199
Combined spinal–epidural for, 200
Epidural anaesthesia for, 200

Local anaesthetic infiltration, 200
Postoperative pain management, 202–4
Principles for anaesthetic management for, 197
Spinal anaesthesia for, 200
Spinal vs. epidural, 199
Spinal vs. general, 199
Uterine rupture after, 175
Calcium, 292–295, 322
Calcium: creatinine ratio, 84
Calcium channel blockers, 136, 137, 141
Calcium gluconate, antidote to MgSO₄, 197
Calcium supplementation, 75
Combined with low-dose aspirin, 106
For pre-eclampsia prevention, 102, 105
Use in under-resourced settings, 110
Captopril, 139, 140
Carboprost, impact on anaesthesia, 190
Cardiac output monitoring devices, 191
Cardiovascular disease,
Antihypertensive use and, 141
Paternal, 81
Risk, 35
Risk factors after pre-eclampsia, 218, 219
Catastrophic antiphospholipid antibody syndrome, 43
Catecholamine release, 191
Central nervous system,
Proteinuria and, 20
White matter lesions, 221
Central venous catheters, 191
Cerebral palsy, 146
Cerebrovascular disease, 35
Cervix,
Ripening of, 175
Unfavourable, 174, 175
Chest pain, 171
CHIPS (Control of Hypertension in Pregnancy Study), 140
Chlamydia, 81
Chlorpromazine promethazine pethidine, cf MgSO₄, 144
Chocolate, higher intake lowers blood pressure, 103
Chronic hypertension, 33
As a risk factor, 79
Estimates for incidence, 64
Renal disease, 187
See also Pre-existing hypertension
Temporal trends in, 65
Timing of delivery in, 174
Chronic kidney disease, 79
Circa-diurnal rhythm of blood pressure, 1
Circulating proteins, 90
Climate and pre-eclampsia trends, 66
CLIP (Community-Level Interventions for Pre-eclampsia) trial, 64, 127
Clonidine, 139, 140
Co-enzyme Q10 supplementation, 107, 109

423
coagulation,
neuraxial analgesia and, 194
tests for pre-eclampsia, 42
coaalopathy, 176
communication,
doctor–patient, 45
with patient, 46
community,
  blood pressure measurement in, 3
  postpartum care, 226
community engagement, 127
community-based care, 126
comorbidity,
  commonly linked to gestational hypertension, 187
  in hypertension, 34
compensatory metabolic acidosis, 191
complete blood count, 42
congenital malformations, 81
congestive cardiac disease and proteinuria, 20
Congo red dot test, 28
connective tissue disorders, 187
continuous spinal analgesia, 195
copper, 105, 109
corticosteroids,
  antenatal, 176
  for fetal lung maturity, 168
  use in expectant care, 169
  use in HELLP syndrome, 148
cost-effectiveness,
  of interventionist care, 174
  of MgSO4, 144, 145
  of prediction, 92
  of proteinuria testing, 26
counselling,
  for expectant vs. interventionist care, 169
  nutritional education, 102
CRADLE BP device, 235
creatinine,
calcium : creatinine ratio, 84
IPG : creatinine ratio, 84
pre-eclampsia risk, 40
serum levels, 43
timing of delivery, 171
crystalloid, intravenous bolus, 198
 cuff,
correct position, 3
correct size, 3
  importance in anaesthesia, 198
dalteparin, 108
DASH (dietary approached to stop hypertension) diet,
  definitions,
  bed rest, 109, 125
  HELLP syndrome, 38
  hypertension, 1
  pre-eclampsia, 37, 266–73
  severe hypertension, 2
  severe pre-eclampsia, 266–73
  significant proteinuria, 26
  systolic and diastolic criteria, 2
delivery,
  indications for in pre-eclampsia, 169, 169
  see also Caesarean section; vaginal delivery
timing and mode, 167–79
demographic risk factors, 78
depression, 82
dexamethasone, 148, 176
diabetes, 78, 79
  antihypertensive use and, 141
  as a risk factor, 79
  chronic hypertension, 187
  pre-gestational, 79
  risk after pre-eclampsia, 220
  diabetic nephropathy, 79
  antihypertensive use and, 141
  diamorphine, 193
diazepam, cf MgSO4, 144
diazoxide, 137, 140
diet,
  GRADE evaluation for best practice points, 345
  international guidelines for recommendations, 346–8
  modifications recommended for all women, 223
  role in pre-eclampsia, 123–4
  weight loss in obesity, 123
dietary changes, 123, 294–299
  for pre-eclampsia prevention, 102, 107, 322–325
  salt restriction, 102
difficult airway, 187, 196
dipsticks,
  for spot albumin : creatinine ratio, 25
  urinary, 21
diuretics, 104, 142, 308, 332
dopamine, renal dose, 135
Doppler,
  fetal status and delivery, 175
  ophthalmic artery, 40
  uterine artery, 40, 84
  velocimetry, 43
  with angiogenic imbalance measures, 45
ductus venosus, 45
dural puncture, 201
dyspnoea, 171
dyslipidae, 171
early delivery, see interventionist care
early warning systems, 190
  response triggering parameters in, 192
eclampsia,
  incidence estimates, 68
  MgSO4 use for, 144
INDEX

prevention, 145, 146
thrombocytopaenia, 189
‘eclampsia box’, 151
education,
    nutritional counselling, 102
    of health care providers, 221
    of women, 46, 221
pre-eclampsia prevention and low rates of, 110
strengthening pre-eclampsia knowledge in women, 49
EmONC, 169
derived CO2 monitoring, 191
diastolic flow in umbilical artery, 45
d-end-organ function,
    complications, 135
    pre-existing hypertension, 215
endothelial dysfunction tests, 86
endothelial–platelet interactions, 86
endotheliosis, glomerular, 19
EOST (Emergency Obstetric Simulation Training), 151, 351–64
epidural analgesia, 193
epidural anaesthesia, 193
to combined spinal–epidural, 194
    continuous spinal analgesia, 195
    vs. parenteral, 193
    vs. spinal in pre-eclampsia, 199
epigenome, 51
epinephrine, 200
equipment,
    availability and choice of care level, 169
    availability and use of local anaesthetic infiltration
    for Caesarean section, 200
    availability in under-resourced settings, 7
    early warning tool, 7
    essential equipment for resuscitation, 186
    for fetal monitoring, 186
    see also devices
    semi-automated, 7
ergometrine, 176
contraindicated in pre-eclampsia, 201
impact on anaesthesia, 190
ESMOE (Essential Steps in Managing Obstetric Emergencies), 151, 351–64
esomeprazole, 148, 150
ethnicity, 141
as a risk factor, 78
exercise,
    and risk, 82
    pre-eclampsia prevention and, 103, 109
    proteinuria and, 20
    role in pre-eclampsia, 124
    stretching, 109
    use in under-resourced settings, 111
    walking, 109
expectant care,
    at 24–33 weeks, 173
    at 34–36 weeks, 173
    at <24 weeks, 172
counselling, 169
health care system and, 169
of HELLP syndrome, 65
risks of, 169
vs. interventionist care, 168
externalising behaviour, 144
factor V Leiden mutation, 79
familial risk factors, 76–8
fentanyl, 197
fetal distress, 136
fetal growth,
    antihypertensives and, 143
    restriction, 69
fetal heart pattern, 141
fetal heart rate, 141
monitoring, 136
fetal lung maturity and corticosteroid use, 168, 169, 176
fetal monitoring, 186
    in pre-eclampsia, 45
    fetal neuroprotection, 146
    fetal testing for pre-eclampsia, 43
    fetal well-being and analgesia, 191
    fetotoxic agents, 143
    fever and proteinuria, 20
    fibrinogen for pre-eclampsia, 42
    fibrinectin, 86
    glycosylated, 45
flavonoids, 103
fluid management,
    GRADE evaluation of best practice points, 365–7
    in pre-eclampsia, 133–5
    international guidelines, 155, 370–81
    restriction in pre-eclampsia, 135
folic acid supplementation, 105
folic-containing multivitamins, 107
pre-eclampsia prevention and, 103
use in under-resourced settings, 111
fullPIERS model, 39, 68
timing of delivery, 171
furosemide, 135
garlic supplementation, 105, 107, 113
gender, fetal, as a risk factor, 81
general anaesthesia, 145, 196
    vs. spinal in pre-eclampsia, 199
genetics,
    familial risk factors for pre-eclampsia, 76
    maternal risk factors, 77
    paternal risk factors, 78
THE FIGO TEXTBOOK OF PREGNANCY HYPERTENSION

genetics continued
thrombophilies, 79
gestational age,
assessment of, 168
in under-resourced settings, 168
methods for, 168
at diagnosis and timing of delivery, 170
blood pressure changes with, 1, 2
mode of delivery and, 175
stillbirth and, 69
timing of delivery, 167, 171
at <24+0 weeks, 172
at 24+0–33+6 weeks, 172
at 34+0–36+6 weeks, 173
at 37+0–42+0 weeks, 174
gestational hypertension,
classification, 34
definition, 35
estimates for incidence, 64
previous, as a risk factor, 80
progression to pre-eclampsia, 67
work up after, 216
glomerular endotheliosis, 19
glomerular proteins, 19
glucose serum levels, 43
GRADE evaluation for best practice points,
classification of hypertensive disorders of pregnancy,
255–6
for anaesthesia, 400
for diet, 345
for fluids drugs and transfusions, 365–7
for hypertension, 236–7
for lifestyle, 345
for mode of delivery, 383
for place of care, 345
for postpartum care, 410
for preventing pre-eclampsia, 340–3
for proteinuria, 250
for timing of delivery, 383
gross motor function, 144
group B streptococci, 81
haematoma, spinal, 202
haemodynamic management, 197
haemoglobin for pre-eclampsia diagnosis, 42
haemorrhage,
potential for, 176
risk, 76
HBPM (home blood pressure monitoring), 6
comprehensive list, 5
use in community, 3
vs. ABPM, 7
headache,
postdural puncture headache, 195, 200, 201
pre-eclampsia risk, 39
timing of delivery, 171
health care workers,
education of, 221
knowledge translation tools, 409
pre-eclampsia prevention and training, 110
self-help training, 151
shortage of, 67, 92
staffing levels, 9
training for blood pressure measurement, 235
training material for, 407–8
health facility, blood pressure measurement in, 5
heart-healthy diet, 107
heat coagulation test, 22
example, 24
interpretation, 23
height, 79
HELLP syndrome,
corticosteroids for, 148
definition, 38
estimates for incidence, 65
ethnicity and, 78
expectant management, 65
imitators, 148
international guidelines for therapy, 156
level of care required, 169
management at 24+0–33+6 weeks, 173
postpartum appearance, 216
therapies for, 147–8, 153
transfusion for, 147
heparin, 148
for pre-eclampsia prevention, 107, 323
hepatic haematoma, 68
hepatic rupture, 68
high-sensitivity C-reactive protein, 86
histidine-rich glycoprotein, 90
HIV, 81
home care, 125
hospital day units, 125
human chorionic gonadotrophin, 86, 88, 89
as part of multivariable analysis, 88, 89
hydralazine, 136, 138, 143
impact on anaesthesia, 190
hydration, 123
hyperlipidaemia, 79
hypertension,
best practice points, 236
chronic, 33
classification of disorders of pregnancy, 34
definition, 1
diagnosis, international guidelines, 240–6
hypertensive response to intubation, 196
mean arterial pressure, 3
measurement of, 1–13
pain-induced sympathetic response, 191
postpartum appearance, 215
postpartum treatment, 215
refractory, 140
risk after pre-eclampsia, 219
severe,
antihypertensive treatment, 135
definition, 2
treatment wall chart, 349
hypertensive disorders of pregnancy,
abstention from alcohol and, 101
associated morbidity and mortality, 66
calcium supplementation, 102
classification, 33–53
common comorbidities, 187
epidemiology, 63–9
estimates on incidence, 63
folate-containing multivitamins, 103
GRADE evaluation for best practice points, 255–6
international guidelines on classification, 257–65
lifestyle changes, 103
low-dose aspirin, 102
management of, 154
non-pharmacological management, 129
risk factors for, 66
timing and mode of delivery, 167–79
hypertensive emergency, 135
hypertensive response to intubation, 196, 393
hypertensive urgency, 135
HYPITAT trial, 40
HYPITAT II trial, 173, 174
hypotension, 188
avoidance of, 198
neuraxial anaesthesia and, 198
spinal analgesia and, 195
hypothyroidism, risk after pre-eclampsia, 220

ICU, refractory hypertension in, 140
immigrant status,
pre-eclampsia risk, 39
pre-eclampsia trends and, 66
immune thrombocytopenia, pre-existing hypertension
and, 41
immunoglobulins, 19
immunosuppression, 44
inattention, 144
incidence,
chronic hypertension, 64
estimates, 63
gestational hypertension, 64
in HIC, 64
in LMIC, 64
late-onset vs. early-onset, 65
pre-eclampsia, 64
temporal trends in, 65
indwelling spinal catheter, 195
infection,
as a risk factor, 81
treatment of for pre-eclampsia prevention, 110
information provision to patient, 46
see also education
inhalation analgesia, 192
inhibin, 86
inositol phosphoglycan-P, 84
interferon-γ, 45
international guidelines,
classification of hypertensive disorders of pregnancy,
257–65
for anaesthesia and analgesia, 205
for classification of pre-eclampsia, 50
for diet, lifestyle and place of care, 129
for fluid, drugs and transfusions, 155
for pre-eclampsia prediction, 288–9
for prevention of pre-eclampsia, 113
for risk factors and predictors, 91
hypertension identification, 12
in proteinuria, 28
mode of delivery, 179, 385–392
postpartum care, 227
recommendations,
for anaesthesia, 402–5
for blood pressure measurement and diagnosis,
240–6
for fluids drugs and transfusions, 370–81
for postpartum care, 414–19
for proteinuria diagnosis, 251–3
on diet, 346–8
on lifestyle, 346–8
on place of care, 346–8
timing of delivery, 178, 385–92
interventionist care,
at 24th–33rd weeks, 172
at 34th–36th weeks, 173
cost-effectiveness of, 174
counselling, 169
vs. expectant, 168, 173
intracerebral haemorrhage and proteinuria, 20
intracervical Foley balloon, 175
intrathecal catheter, 195
intrathecal morphine, 204
intrauterine growth restriction, 36, 45
diagnosis, 168
early-onset, 150
induction of labour and, 175
intubation,
hypertensive response to, 196
prevention of, 393
iodine, 105, 109
IPG: creatinine ratio, 84
iron, 109
iron supplements, 105
ischaemic heart disease risk after pre-eclampsia,
219
isradipine, 137
ketamine, 203
ketanserin, 137
knowledge translation tools, 409

L-arginine, 148, 149
for pre-eclampsia prevention, 108, 336
labetalol, 135, 136, 138, 139, 141, 142
hypertensive response to intubation, 197
impact on anaesthesia, 190
paediatric neurodevelopment and, 143
laboratory markers, 85
labour induction, 175
in women with gestational hypertension, 174
lactate dehydrogenase, serum levels, 43
large for gestational age, risk in pre-eclampsia, 35
last menstrual period,
assessment of gestational age, 168
memory aids for, 168
leptin, 45
lidocaine, 200
lifestyle,
changes, 312
changes for cardiovascular risk, 223
changes for pre-eclampsia prevention, 103, 108, 326
GRADE evaluation for best practice points, 345
international guidelines for recommendations, 346–8
modifications recommended for all women, 223
role in pre-eclampsia, 124
use in under-resourced settings, 112
literature searches, 275–6
LMICs, see under-resourced settings
long-term paediatric neurodevelopment, 143
low-dose aspirin, 75
low-molecular-weight heparin, 107, 108
use in under-resourced settings, 112
lupus nephropathy, 79

magnesium sulphate, 137
analgesic effect, 203
antihypertensives in non-severe hypertension, 153
Caesarean delivery after, 145
contraindication for non-depolarising muscle relaxants, 197
cost-effectiveness, 144, 145
dose reduction, 145
for eclampsia treatment, 144
for pre-eclampsia treatment, 144
impact on anaesthesia, 190
implications for anaesthesia, 187
international guidelines, 156
intramuscular administration, 350
obesity and dose required, 146
policy brief, 369
treatment wall chart, 350
use in expectant care, 169
magnesium supplementation, 103, 109
malaria, 81
Malawi Demographic Health Survey, equipment availability, 7
MAP (mean arterial pressure), 3, 88, 89
as part of multivariable analysis, 89
masked hypertension, 34, 40
maternal birth weight, 79
maternal placental syndrome, 220
mean arterial pressure in hypertension in pregnancy, 3, 88, 89
measurements,
importance of repeat blood pressure measurements, 2
of hypertension, 1–13
of proteinuria, 19–29
medical history,
as a risk factor, 79
paternal, 81
medullary sponge kidney, 142
memory aids for remembering last menstrual period, 168
meningitis, 202
mental health,
as a risk factor, 82
risks after pre-eclampsia, 221
MEOWS (Modified Early Obstetric Warning Systems), 191
mercury sphygmomanometer, 5
metformin, for pre-eclampsia prevention, 109
methyldopa, 137, 139, 141
paediatric neurodevelopment and, 143
use of, 142
Microlife 3AS1-2 hand-held device, 10, 235
micronutrients, 298–303
deficiencies and risk, 82
for pre-eclampsia prevention, 103, 109, 328
minimally invasive cardiac output monitoring devices, 191
miniPIERS model, 48, 68
timing of delivery, 171
miscarriage, previous, as a risk factor, 80
misoprostol, 175
impact on anaesthesia, 190
mode of delivery,
at 34th–36th weeks, 174
choice of; 175–6
priorities for, 178
see also Caesarean section; vaginal delivery
monitoring for anaesthesia, 187
morbidity,
associated with hypertensive disorders of pregnancy, 66
early anaesthetic assessment and reduction in, 185
excess in interventionist care at 24th–33rd weeks, 172
interventionist care and, 173

maternal,
  associated with hypertensive disorders of pregnancy, 66
  rates of, 68
  timing of delivery at 34\textsuperscript{th}–36\textsuperscript{th} weeks, 173

neonatal,
  respiratory, 173
  timing of delivery at 34\textsuperscript{th}–36\textsuperscript{th} weeks, 173

perinatal, 69

mortality,
in LMICs, 66

maternal,
  associated with hypertensive disorders of pregnancy, 66
  rate in Sri Lanka, 49
  rate in UK, 48

neonatal, 69

perinatal, 69

MTHFR single nucleotide polymorphism, 79

multiple pregnancy,
as a risk factor, 80
  pre-eclampsia risk, 39

multivitamins, folic acid-containing, 107

neuraxial analgesia,
cf parenteral, 193
  choice of route in pre-eclampsia, 199
  combined spinal–epidural for, 194, 200
  contraindications, 193
  epidural, 193
  for Caesarean section, 199, 200
  hypotension and, 198
  neuroanatomy for needle placement, 187
  postoperative, 204
  postoperative complications, 202
  single-shot spinal analgesia, 195

neurodevelopment,
  long-term, 143
  paediatric, 217
  neuroprotection, 146

neutrophil gelatinase-associated lipocalin, 45

nifedipine, 136, 138, 141
  hypertensive response to intubation, 197
  impact on anaesthesia, 190
  implications for anaesthesia, 187
  paediatric neurodevelopment and, 143

use of, 142

nitric oxide donors for pre-eclampsia prevention, 110, 310, 338

nitric oxide production, 148

nitroglycerin infusion, 139

nitrous oxide/oxygen, 192

non-alcoholic steatohepatitis, pre-existing hypertension and, 41

non-depolarising muscle relaxants, 197

non-pre-eclampsia glomerular disease, persistent proteinuria and, 20

non-steroidal anti-inflammatory drugs, 203

obesity,
  and anaesthesia, 187
  bariatric surgery for, 224
  blood pressure changes with, 2
  choice of cuff size, 3
  dietary changes for pre-eclampsia prevention, 107
  dose of MgSO\textsubscript{4} and, 146
  pre-existing hypertension and, 41
  weight loss in, 123

oedema,
  laryngeal, 188
  of airway, 196
  pre-eclampsia definition and, 37
  oestradiol, 175

oligohydramnios, 45, 69
  induction of labour and, 175

oliguria, 135
  and anaesthesia, 188
  pre-eclampsia risk, 39

online calculator, 48
  for pre-eclampsia risk, 39

ophthalmic artery, Doppler imaging, 40

opioids,
  for parenteral analgesia, 193
  hypertensive response to intubation, 197
  intrathecal, 204
  intravenous, 203
  oral, 203

orthostasis, 20

out-of-hospital care, 125

outpatient care, 125

oxidative stress, 86, 104

oxygen saturation,
  for pre-eclampsia, 42
  pre-eclampsia risk, 39

oxytocin, 176, 201
  impact on anaesthesia, 190, 190

pain,
  analgesia in labour, 191
  control of, 202
pain continued
physiological effects of, 202
postoperative management, 202–4
PAPP-A, 86, 88, 89
as part of multivariable analysis, 88, 89, 90
paracetamol, 203
parenteral analgesia, 192
parity,
as a risk factor, 80
blood pressure changes with, 2
pre-eclampsia risk, 39
timing of delivery, 171
paternal risk factors, 78
patient advocacy, 45
patient perspective in pre-eclampsia, 45
patient-controlled analgesia, 193, 203
PELICAN study, 44
periodontal disease, 81, 110, 314
persistent proteinuria, 20
pethidine, 193
phaeochromocytoma, 43
phenotype for pre-eclampsia, 44
phenylephrine, 198
phenytoin, cf MgSO4, 144
physical activity and pre-eclampsia, 124
phytonutrient supplementation, 109
placental abruption, 39
risk in pre-existing hypertension, 35
timing of delivery in chronic hypertension, 174
placental growth factor, 44, 86, 86, 88, 89
as part of multivariable analysis, 89
ratio to sFlt-1, 87
role in pre-eclampsia, 36
placental perfusion, 86
plasma volume expansion, 133
platelet count,
tests for pre-eclampsia, 42
timing of delivery, 171
platelet distribution width, 39
platelet transfusion, 147
podocyturia as a predictor, 84
point-of-care paper-based microfluidic diagnostic stamps, 28
policy briefs,
for antihypertensive therapy, 368
for blood pressure measurement, 238
for MgSO4 treatment, 369
for postpartum care, 412
for proteinuria, 247
sample policy brief for blood pressure measurement, 238
position for blood pressure measurement, 3
post-traumatic stress disorder, 45, 201
risks of pre-eclampsia, 221
postdural puncture headache, 195, 200, 201
posterior reversible leukoencephalopathy syndrome, 39
postpartum care, 215–27
GRADE evaluation of best practice points, 410
international guidelines, 414–19
policy brief, 412
priorities for in under-resourced settings, 226
potassium, increased intake, 123
poverty and pre-eclampsia prevention, 110
PP-13 as part of multivariable analysis, 88
pravastatin, 148
pre-eclampsia,
adverse conditions of, 39
adverse conditions that define it, 38
biomarkers for, 44
choice of anaesthesia for, 199
choice of antihypertensive treatment in, 136
choice of neuraxial anaesthesia for, 199
classification, 34
definitions, 35, 37, 266–73
diet and, 123–4
early-onset, causes, 36
effect on offspring health, 144
estimates for incidence, 64
familial risk factors, 76–8
fluid management in, 133–5
fluid restriction, 135
health issues in offspring, 218
imitators of, 43
impact of classification, 52
indications for delivery, 169
international clinical guidelines for prediction, 288–9
late-onset, causes, 37
late-onset vs. early-onset incidence, 65
long-term maternal health after, 218–21
management of, 134
maternal testing in suspected, 41, 42
MgSO4 use for, 144
model for, 36
novel therapies for, 148
origins, 35
paediatric neurodevelopment after, 217
planning future pregnancies after, 217
paternal risk factors, 78
performance of predictive tests for pre-eclampsia, 277–87
phenotypes of, 44
planning future pregnancies after, 217
post-traumatic stress after, 45
postpartum work up after, 217
prediction, 82–90
predictors for, 75–92
prevention, 101–13
best practice points, 340–3
in intermediate-risk women, 105
previous as a risk factor, 80
recognition of risks, 169
risk factors for, 75–92
risk markers for, 77
risks of general anaesthesia in, 196
severe,
  definition, 37, 171, 266–73
risks of expectant care, 169
systemic effects on anaesthesia, 188–9
trials and reviews of interventions for prevention,
  291–315, 316–39
pre-existing hypertension,
classification, 34
definition, 35
investigations for, 41
postpartum treatment, 215
screening for after pre-eclampsia, 217
pre-existing medical conditions, 79
pre-gestational diabetes, 79
prediction, 82–90
  multivariable analyses, 87–90
  priorities for, 92
  univariable analyses, 83–7
    blood pressure, 83
calcium, 84
laboratory markers, 85
podocyturia, 84
proteinuria, 83
predictors,
  angiogenic factors, 86
  endothelial dysfunction tests, 86
  for adverse outcomes, 171
  for pre-eclampsia, 75–92
  maternal characteristics plus biomarkers, 88
  performance of predictive tests for pre-eclampsia,
    277–87
  warning signs and symptoms, 127
pregnancy,
  balancing prolongation with delivery risk, 167
  choice of BPM device for, 5
  complications in offspring after pre-eclampsia, 218
  planning future pregnancies, 217
  recommended weight gain during, 124
  trials and reviews of interventions for prevention of
    pre-eclampsia, 291–315, 316–39
pregnancy interval as a risk factor, 80
pregnancy-induced hypertension and confusion, 35
prematurity, complications associated with, 169
preterm delivery,
  complications associated with, 169
  risk in pre-existing hypertension, 35
prevention,
in women at low-risk, 101–5
  of pre-eclampsia, 101–13
  trials and reviews of interventions for prevention of
    pre-eclampsia, 291–315, 316–39
primipaternity, 81
priorities in urine testing, 27, 28
priorities for future research,
biomarkers, 51
for anaesthesia and analgesia, 207
for classification of pre-eclampsia, 52
for diet lifestyle and place of care, 130
for epidemiology, 69
for fluid drugs and transfusions, 156
for hypertension identification, 13
for prevention of pre-eclampsia, 114
for risk factors and predictors, 91
in proteinuria, 29
postpartum care, 227
precision medicine, 52
timing and mode of delivery, 179
priorities for under-resourced settings,
diagnosis of hypertensive disorders of pregnancy, 47
for anaesthesia and analgesia, 205
for classification of pre-eclampsia, 47
for diet lifestyle and place of care, 129
for fluid drugs and transfusions, 154
for risk factors and predictors, 91–2
hypertension identification, 12
in proteinuria, 27
postpartum treatment, 225
timing and mode of delivery, 177
prioritisation of urine testing, 28
proangiogenic factors, 86
probiotics, 103
prolonged labour, 76
prolonged neuromuscular block, 197
prophylaxis, 75
propofol, 197
prostacyclin, 137
prostaglandin E2, 175
prostaglandin precursors, 104, 304
  for pre-eclampsia prevention, 109, 330
proteinuria,
  and anaesthesia, 188
  antihypertensive use and, 141
  as a predictor, 83
  best practice points, 250
  causes of, 19, 20
  cost considerations for testing, 26
  cost-effective testing, 26
  definition of significant proteinuria, 26
  detection of, 20
  dipstick testing, 21
  heat coagulation test, 22
  international guidelines for diagnosis, 251–3
  measurement of, 19–29
  in antenatal care, 9
  methods of assessment, 248
  normal levels, 19
  persistent, 20
  policy brief, 247
  prioritisation of urine testing, 28
  screening for, 20
proteinuria continued
  self-test, 27
  spot albumin : creatinine ratio, 25
  spot protein : creatinine ratio, 24
  sulfosalicylic acid testing, 23
  timed urine collection, 26
  timing of delivery, 171
  transient, 19
prothrombin gene mutation, 79
proton pump inhibitors, 150
pulmonary artery catheters, 191
pulmonary oedema, 39, 135
  and anaesthesia, 188
pyridoxine, 105, 109

rainy season and pre-eclampsia trends, 66
relative rise in blood pressure, 3
relaxation techniques, 141
remifentanil, 193, 197
renal disease,
  and anaesthesia, 187
  exacerbation postpartum, 216
  pre-existing and proteinuria, 20
  risk after pre-eclampsia, 220
renal function, 86
renal parenchymal disease, 35
resistant hypertension, definition, 37
respiratory alkalosis, 191
respiratory failure, 201
rest,
  bed rest, 109, 125
  increased, 109
restricting therapy, 145
resuscitation,
  after parenteral analgesia, 193
  equipment for, 185
  essential equipment for, 186
  maternal, 186
  neonatal, 186
retinal detachment, 68
risk factors,
  age, 78
  balancing pregnancy prolongation with delivery risk,
    167
demographic, 78
  ethnicity, 78
familial, 76–8
  for cardiovascular disease after pre-eclampsia, 218, 219
  for hypertensive disorders of pregnancy, 66
  for pre-eclampsia, 75–92
identification of for timing of delivery, 171
identification of women at risk in LMICs, 75
past medical history, 85
paternal, 81
performance of predictive tests for pre-eclampsia,
  277–87
pregnancy-associated, 80
risk markers for pre-eclampsia, 77
screening for cardiovascular risk factors, 222
road infrastructure, 126
S100B, 45, 51
S-nitrosoglutathione, 148, 149
salt, reduced intake, 107, 123, 124
  pre-eclampsia prevention and, 102
sample policy brief for blood pressure measurement,
  238
SCOPE Consortium cohort, 88
Scottish paradigm for antenatal care, 33
screening,
  cost-effectiveness in proteinuria, 26
  for cardiovascular risk factors, 222
  for pre-existing hypertension after pre-eclampsia, 217
  for proteinuria, 20
  for thrombophilia after pre-eclampsia, 217
seizures and proteinuria, 20
selenium supplementation, 105, 109
sepsis,
  proteinuria and, 20
  risk, 76
serum chemistry for pre-eclampsia, 43
settings,
  appropriate levels of care, 169
  best practice points for place of care, 345
  choice of device for, 6
  community-based care, 126
  community-based engagement, 127
  facility vs. community, 48
  for blood pressure measurement, 5
  home care, 125
  hospital day units, 125
  international guidelines for recommendations on
    place of care, 346–8
  out-of-hospital care, 125
  outpatient care, 125
  postpartum care in community, 226
  transport to facility, 126
severe hypertension, see hypertension, severe
sFlt-1, 44
  levels in multiple pregnancy, 80
  ratio to PlGF, 87
shivering,
  cuff size and, 198
  with epidural anaesthesia, 200
sildenafil, 148
single nucleotide polymorphisms,
  MTHFR, 79
prothrombin, 79
single-shot spinal analgesia, 195
small for gestational age,
  antihypertensive use and, 140
  interventionist care at 24\textsuperscript{th}–33\textsuperscript{th} weeks, 172
  risk in pre-eclampsia, 35
  risk in pre-existing hypertension, 35
smartphone technology, links to BPM devices, 8
smoking,
  as a risk factor, 82
  cessation, 306
  pre-eclampsia prevention and cessation, 104, 330
snails, 105
socioeconomic status, 82
sodium intake, 124
solar power for BPM devices, 8
sperm exposure, 81
spinal anaesthesia,
  vs. epidural in pre-eclampsia, 199
  vs. general anaesthesia in pre-eclampsia, 199
spinal neuroanatomy, 187
spot albumin : creatinine ratio, 25
spot protein : creatinine ratio, 24
standardising care, 151
stature, 79
stillbirth, 39
  antihypertensives and, 143
  incidence, 69
  risk and proteinuria, 26
  risk in pre-existing hypertension, 35
  timing of delivery in chronic hypertension, 174
stress,
  management and pre-eclampsia, 124
  post-traumatic, 45
  reduction, 112
stroke, 68, 196
  incidence, 68
  risk after pre-eclampsia, 220
  risk markers for, 135
  thrombocytopaenia, 189
subarachnoid haemorrhage, 189
proteinuria and, 20
sulfosalicylic acid testing, 23
supplementation,
  calcium, 75
  folate-containing multivitamins, 103
  high-protein, 102
  isocaloric protein, 102
  magnesium, 103
  micronutrients, 103
  phytonutrients, 104
  protein/energy supplements in undernourished
    women, 102
  pyridoxine, 104
  selenium, 105, 109
  vitamins, 104, 105
zinc, 104
surveillance, for risk factors, 75
symphysis–fundal height, assessment of gestational age, 168
systemic lupus erythematosus, 216
tablet technology, links to BPM devices, 8
Tamm–Horsfall protein, 19
taurine as part of multivariable analysis, 89
temporal trends, 65
thiazide diuretics, 142, 308
  pre-eclampsia prevention and, 104, 352
thiopental, 197
three-delay model, 126
thrombocytopaenia, 176
  and anaesthesia, 189
thromboembolic disease, interventionist care, 173
thrombophilias,
  as a risk factor, 79
  screening for after pre-eclampsia, 217
thromboprophylaxis, 148
  postpartum, 216
thrombosis, 43
thrombotic thrombocytopaenic purpura, 148
thrombotic thrombocytopaenic purpura–haemolytic
  uraemic syndrome, 43, 216
thyroid-stimulating hormone, elevated, 220
thyroxine-binding prealbumin, 19
timed urine collection, 26
timing of delivery, 167
  at 24\textsuperscript{th}–33\textsuperscript{th} weeks, 172
  at 34\textsuperscript{th}–36\textsuperscript{th} weeks, 173
  at 37\textsuperscript{th}–42\textsuperscript{nd} weeks, 174
  at <24\textsuperscript{th} weeks, 172
  consideration of pre-eclampsia severity, 171
  gestational age at diagnosis and, 170
  identification of risk factors and, 171
  in women with chronic hypertension, 174
  in women with gestational hypertension, 174
  in women with pre-existing hypertension, 174
  predicting adverse outcome, 171
  priorities for, 178
  tinzaparin, 108
  traditional medicines, 105
  traffic light early warning system, 8
training,
  emergency obstetric simulation training, 351–64
  for health care workers, 10
  health care workers for blood pressure measurement, 235
  knowledge translation tools, 409
  material for health care workers, 407–8
  of health workers, 67
  pre-eclampsia prevention and training of health care
    workers, 110
tramadol, 193
transferrin, 19
transfusion,
GRADE evaluation of best practice points, 365–7
international clinical guidelines for, 370–81
use in HELLP syndrome, 147
transient hypertensive effect, classification, 34
transient proteinuria, 19
transport,
delays and mortality, 67
delays in, 126
road infrastructure, 126
to care facility, 126
transthoracic echocardiography, 191
transversus abdominis plane blocks, 204
treatment,
delays and mortality, 67
delays in, 126
standardising care, 151
treatment postpartum, 215–27
triage,
delays and mortality, 67
delays in, 126
trisomy 21, 85
tubular disease, persistent proteinuria and, 20
tubular proteins, 19

ultrasound,
assessing gestational age, 168
availability in LMICs, 168
umbilical artery, end-diastolic flow in, 45
under-resourced settings,
antenatal care in, 8
assessment of gestational age in, 168
blood pressure measurement in, 7–10
heat coagulation test for proteinuria in, 22
road infrastructure, 126
traffic light early warning system, 8
transport to facility in, 126
undernourished women, 102
urapidil, 137
uric acid,
pre-eclampsia risk, 39, 39, 40
serum levels, 43
urinary dipsticks,
automated testing of, 22
visual interpretation of, 21
urinary sediment, 216
urine testing,
for pre-eclampsia, 42
for proteinuria, 21–6
uterine artery, 43
as part of multivariable analysis, 90
Doppler imaging, 40, 84
Doppler imaging and delivery, 175
pulsatility index, 88, 89
uterine rupture, 175

vaginal delivery at 34th–36th weeks, 174
vascular resistance, 86
vasopressors, 198
verbal ability, 144
visual disturbances and pre-eclampsia risk, 39
visual interpretation of urinary dipsticks, 21
visual symptoms, timing of delivery, 171
vitamin A, 105, 109
vitamin C, 308
deficiency and risk, 82
pre-eclampsia prevention and, 104, 109, 332
vitamin D,
deficiency and risk, 82
pre-eclampsia prevention and, 105
vitamin E, 308
deficiency and risk, 82
pre-eclampsia prevention and, 104, 109, 332
wall chart,
hypertension treatment, 349
MgSO4 treatment, 350
weight,
extremes of and pre-eclampsia risk, 39
recommended weight gain during pregnancy, 124
weight gain,
between pregnancies, 108
pre-eclampsia definition and, 37
white blood cell count for pre-eclampsia, 42
white coat effect, 40
WHO analgesic ladder, 202
WHO prediction test, 83
WHO recommendations, for antenatal care, 9
work, physically demanding, 109
workload,
reduction, 109
role in pre-eclampsia, 124
wound infiltration, 204

yoga, 112
zinc supplementation, 104, 109